Clinical trials: Tenosynovial Giant Cell Tumor, Diffuse, open to volunteers
Tenosynovial Giant Cell Tumor
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
- Trial name
- NCT07499362
- Testing
- Pimicotinib
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Tenosynovial Giant Cell Tumor, Diffuse
Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor
Tenosynovial giant cell tumor (TGCT) is a rare neoplasm predominantly occurring in young and middle-aged adults, characterized by high recurrence and high disability rates. Surgery represents the first-line treatment at present.
- Trial name
- NEXPERT (NCT07707882)
- Testing
- Pimicotinib, Tumor resection surgery
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Synovitis Villonodular
Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis
Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction.
- Trial name
- SYVIPRO (NCT07503821)
- Testing
- synovial biopsy
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital